ISRCTN12461724已完成未知
HbA1c TargeT AcheIvemeNt in diabeteS. Psychometric and biomedical outcomes of HbA1c target-setting in adults with Type 1 and Type 2 diabetes: A mixed-methods parallel-group randomised feasibility study
St Helens and Knowsley Teaching Hospitals NHS Trust0 个研究点目标入组 50 人开始时间: 2021年6月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36302049/ (added 28/10/2022) 2023 Abstract results in https://doi.org/10.1111/dme.15048 Abstracts P300, P302 and P303. Presented at the Diabetes UK Professional Conference 2023. (added 04/08/2023) 2023 Abstract results in https://doi.org/10.2337/db23-1056-P Presented at the American Diabetes Association (ADA) conference (added 04/08/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Sub-study A:
- •1. Aged 18 and over.
- •2. Has Type 1 or Type 2 Diabetes.
- •3. HbA1c >/=64;
- •Sub-study B:
- •1. Enrolled in study A.
- •Sub-study C:
- •1. Healthcare professional directly involved in the care of people with diabetes.
- •Sub-study D:
- •1. Eligible patients declining entry into sub-study A will be approached for inclusion in study D.
排除标准
- •Sub-study A:
- •1. Patients at risk of CVD events.
- •2. Patients with an episode of severe hypoglycaemia with the past 12 months.
- •3. Patients with hypoglycaemia unawareness (defined as a GOLD score =4).
- •4. Patients unwilling to self-monitor blood glucose at home (if clinical management requires).
- •5. Patients unwilling to inject insulin (if clinical management requires).
- •6. BMI =45 kg/m².
- •7. Patients who have opted-out from being contacted by researchers under the NHS national data opt-out service.
- •8. Patients with other serious illnesses which may limit survival or factors which may limit adherence to study interventions.
- •9. Patients currently participating in another clinical trial.
- •10. Patients with a transplanted organ.
- •11. Pregnancy.
- •12. Patients with requirements for regular blood transfusion or venesection.
- •13. Ongoing medical therapy known to cause difficulties with glycaemic control (e.g. corticosteroid therapy).
研究者
相似试验
已完成
不适用
Accuracy of Hemoglobin A1C to Predict Glycemia in HIVHIVDiabetesHyperglycemiaNCT00433628National Institute of Allergy and Infectious Diseases (NIAID)175
已完成
不适用
Influence of erythropoietin simulating agents and iron therapy on HbA1cISRCTN52414847Hull and East Yorkshire Hospitals NHS Trust (UK)30
已完成
不适用
Risk Assessment of Type 2 Diabetes in PharmaciesType2 DiabetesNCT03979768University of Bergen368
已完成
不适用
Evaluation of annual fluctuation of HbA1c of diabetes patients.type 2 diabetes mellitus (T2DM)JPRN-UMIN000014977Inobe hospital100
进行中(未招募)
不适用
Assessment of blood glucose profile in type 2 diabetic patients after a one-week treatment with gliclazide 60 mg MR using both the glycaemic Holter method and multiple blood glucose samples.A double-blind, randomized, parallel group, placebo-controlled, exploratory study.Type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2008-002647-16-GBInstitut de Recherches Internationales Servier
